Doctors at the Urology Group are pioneering the use of artificial intelligence to enhance prostate cancer treatment, offering ...

The FDA has approved the Vanquish Water Vapor Ablation System, which uses steam to destroy prostate tumors. However, the ...

The recent FDA approval of the IsoPSA blood test may represent a notable advancement in prostate cancer screening and diagnosis. Developed by Cleveland Diagnostics, the in vitro diagnostic instrument ...

Nonlinear improvement seen in relative benefit of distant metastasis, OS, with reduced benefits beyond nine to 12 months of ADT.

The treatment is suitable for men whose cancer has not spread outside of the prostate gland or has spread to the area just ...

The PROSTATE-IQ trial uses the ArteraAI Prostate Test to personalize treatment for prostate cancer recurrence post-prostatectomy, potentially reducing hormone therapy use. The trial stratifies ...

Talzenna plus Xtandi showed a 14-month survival improvement for HRR gene-mutated metastatic castration-resistant prostate cancer, supported by TALAPRO-2 trial data. Nubeqa approval for metastatic ...

The FDA has approved a novel diagnostic for prostate cancer that looks to improve upon the common screener for ...

Telix Pharmaceuticals has dosed its first patient for the second part of a global study to evaluate the lead prostate cancer ...

A study co-led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center found that most of the benefits of ...

In this retrospective cohort study, researchers investigated the association between travel time and mortality in prostate cancer patients.

A 68-year-old man presented to the emergency department with haematuria and penile pain. His medical history included benign prostatic hyperplasia, but no follow-up examinations had been performed.